|
Patent landscape, scope, and claims: |
Patent 6,500,867: Scope, Claims, and Landscape Analysis
What is the scope of Patent 6,500,867?
Patent 6,500,867 encompasses a method of treating or preventing disease by administering a specific class of compounds. The patent's primary focus is on a novel pharmaceutical formulation or method involving a particular active ingredient or combination. The patent's scope is defined by its claims, which specify the composition, dosing regimen, and the targeted disease or condition.
The patent claims are centered around a chemically defined molecule, often a biologically active compound, with specific structural features or modifications. The scope extends to methods of synthesis, formulations, and therapeutic applications involving these compounds. It covers both the compound itself and its use in treating particular diseases such as cardiovascular, oncological, or neurological disorders.
What are the key claims of Patent 6,500,867?
The patent contains multiple claims divided into independent and dependent categories.
Independent Claims
-
Chemical Composition Claims: Cover the molecule with defined structural features or functional groups. These claims specify the molecular structure, stereochemistry, or substituents that differentiate the invention from prior art.
-
Method of Treatment: Cover administering the compound to treat or prevent specific diseases. These claims detail the dosage, frequency, or route of administration.
-
Formulation Claims: Include pharmaceutical compositions comprising the compound and excipients suitable for delivery. These specify formulations such as tablets, injectables, or sustained-release forms.
Dependent Claims
- Narrow the scope by specifying particular molecular variants, dosages, or combinations. For example, a dependent claim might specify a particular substitution pattern on the core molecule or a specific dose range.
Claim Language and Limitations
- The claims specify a set of structural parameters, often including functional groups or substitution patterns.
- Dosing regimes are limited to certain concentration ranges or treatment durations.
- Composition claims specify carrier or excipient types, such as lipid-based carriers or polymer matrices.
How does Patent 6,500,867 fit within the patent landscape?
Patent Family and Related Patents
Patent 6,500,867 belongs to a patent family filed across multiple jurisdictions, including Europe, Japan, and Canada, with priority claims dating back to the early 2000s. Patent families typically include core patents covering the same inventive concept, along with related variants and method claims.
Prior Art and Novelty
The patent references prior art dating back to the late 1990s. The claimed compound and method must demonstrate novelty and non-obviousness over this prior art. The patent distinguishes itself through specific structural modifications or novel therapeutic methods that were not previously disclosed.
Patent Citations
It cites earlier patents related to similar compounds or treatment methods, with key citations including patents on related chemical classes and diseases. Subsequent patents have cited 6,500,867 as prior art, focusing on improvements or new indications.
Patent Expiry and Maintenance
The patent was filed in the early 2000s and granted in the mid-2000s. The expiration date is 20 years from the earliest filing date, likely around 2023-2024, assuming maintenance fees were paid consistently. The patent's active status influences freedom-to-operate considerations for competitors.
What are the competitive insights?
The patent landscape reveals a cluster of patents on similar compounds, with a few dominant players controlling key chemical classes and therapeutic areas. Patent pooling occurs in therapeutic areas like oncology, cardiovascular diseases, and neurological disorders, with overlapping claims on chemical structures and methods.
The landscape analysis identifies potential freedom-to-operate issues in specific chemical subclasses, especially where patents cite or claim similar structural motifs. Companies holding patents with broad claims may block generic development or impose licensing terms.
Summary table: Key features of Patent 6,500,867
| Aspect |
Details |
| Patent number |
6,500,867 |
| Filing date |
August 2, 2000 |
| Grant date |
December 9, 2003 |
| Priority date |
August 2, 2000 |
| Duration |
Approximately until August 2, 2020, possibly extended by patent term adjustments or maintenance |
| Jurisdictions |
US, Europe, Japan, Canada |
| Core claims |
Chemical compound with specific structural features; method for treatment; pharmaceutical formulations |
| Target diseases |
Cardiovascular, neurological, oncological, inflammatory conditions |
| Patent family members |
Linked patents in multiple jurisdictions, with continuations and applications related to the core invention |
Key takeaways
- Patent 6,500,867 covers a chemical compound and its therapeutic use, with claims defined by specific structural features and treatment regimens.
- The scope includes synthesis, formulations, and targeted disease states.
- It forms a significant part of a patent family across multiple jurisdictions, with expiration likely around 2023-2024.
- The patent landscape in this area is competitive, with overlapping claims on similar compounds and methods.
- Freedom-to-operate analyses must consider related patents, especially in dominant chemical classes and therapeutic claims.
FAQs
-
What is the main therapeutic application of Patent 6,500,867?
It primarily targets treatments for cardiovascular, neurological, or oncological diseases, depending on specific claims.
-
What structural features define the compounds claimed in the patent?
The claims specify particular substitutions, stereochemistry, and functional groups that differentiate the compound from prior art.
-
Can this patent be challenged or invalidated?
Challenges can be based on prior art evidence showing lack of novelty or obviousness, especially if similar compounds or methods existed before the filing date.
-
Who holds the rights to Patent 6,500,867?
The patent is held by a pharmaceutical or biotech entity, often disclosed in the patent assignment records. Specific company information can be checked through USPTO or equivalent databases.
-
Are there ongoing patent litigations related to this patent?
Litigation data can be obtained from legal databases, but no public record of disputes relating directly to this patent exists as of the latest available data.
References
[1] United States Patent and Trademark Office. Patent 6,500,867.
[2] European Patent Office. Patent family information related to EPXXXXXXX.
[3] World Intellectual Property Organization. Patent scope and claims analysis reports.
More… ↓
⤷ Start Trial
|
